Delcath Systems, Inc. (NASDAQ:DCTH) Shares Purchased by Palisades Investment Partners LLC

Palisades Investment Partners LLC raised its holdings in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 13.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 169,327 shares of the company's stock after purchasing an additional 19,671 shares during the period. Palisades Investment Partners LLC owned about 0.53% of Delcath Systems worth $2,039,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Barclays PLC acquired a new stake in shares of Delcath Systems in the third quarter worth approximately $104,000. Baader Bank Aktiengesellschaft acquired a new stake in shares of Delcath Systems in the fourth quarter worth approximately $204,000. Principal Financial Group Inc. boosted its stake in shares of Delcath Systems by 28.8% in the fourth quarter. Principal Financial Group Inc. now owns 115,183 shares of the company's stock worth $1,387,000 after acquiring an additional 25,736 shares during the last quarter. Private Advisor Group LLC acquired a new stake in shares of Delcath Systems in the fourth quarter worth approximately $153,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Delcath Systems in the fourth quarter worth approximately $156,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. HC Wainwright lifted their price target on Delcath Systems from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Friday. Wall Street Zen upgraded Delcath Systems from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $24.00.

Delcath Systems Price Performance

Shares of Delcath Systems stock traded down $0.04 during trading hours on Friday, hitting $16.11. The company had a trading volume of 551,896 shares, compared to its average volume of 372,067. The company's 50-day moving average is $13.05 and its two-hundred day moving average is $12.98. Delcath Systems, Inc. has a twelve month low of $6.33 and a twelve month high of $18.23. The company has a market cap of $561.05 million, a P/E ratio of -11.93 and a beta of 0.72.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). The business had revenue of $19.80 million for the quarter, compared to analyst estimates of $16.83 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. Sell-side analysts expect that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.